Water intoxication in man after cyclophosphamide therapy

Time course and relation to drug activation

Ralph A Defronzo, H. Braine, O. M. Colvin, P. J. Davis

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Cyclophosphamide therapy in doses greater than 50 mg/kg body weight has resulted in frank impairment of water excretion in 17 of 19 normally hydrated patients with cancer. Clinically, these patients developed hyponatremia, weight gain, and inappropriately concentrated urine during cyclophosphamide infusion, but without cyclophosphamide they excreted water loads normally. The decrease in serum osmolarity (range, 5 to 41 milliosmols/litre) and rise in urine osmolarity (range, 309 to 798 milliosmols/litre) occurred 4 to 12 hours after cyclophosphamide infusion, lasted up to 20 hours, and was related temporally with the urinary excretion of active alkylating metabolite(s) of the drug. Treatment of four cancer patients with cytosine arabinoside failed to provoke water intoxication. The mechanism of cyclophosphamide induced impairment of water excretion is unclear. Tumor release of antidiuretic hormone after cyclophosphamide administration seems unlikely since the study group included patients with leukemia and aplastic anemia without tumor. The likelihood and self limited time course of impaired water excretion during high dose cyclophosphamide treatment should be recognized because such patients are invariably waterloaded to prevent uric acid lithiasis and drug related cystitis.

Original languageEnglish (US)
Pages (from-to)861-869
Number of pages9
JournalAnnals of Internal Medicine
Volume78
Issue number6
StatePublished - 1973
Externally publishedYes

Fingerprint

Water Intoxication
Cyclophosphamide
Water
Osmolar Concentration
Therapeutics
Neoplasms
Urine
Lithiasis
Cystitis
Hyponatremia
Aplastic Anemia
Cytarabine
Metabolic Activation
Uric Acid
Vasopressins
Pharmaceutical Preparations
Weight Gain
Leukemia
Body Weight

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Water intoxication in man after cyclophosphamide therapy : Time course and relation to drug activation. / Defronzo, Ralph A; Braine, H.; Colvin, O. M.; Davis, P. J.

In: Annals of Internal Medicine, Vol. 78, No. 6, 1973, p. 861-869.

Research output: Contribution to journalArticle

@article{75c928fd53d34598b60d573335355bdb,
title = "Water intoxication in man after cyclophosphamide therapy: Time course and relation to drug activation",
abstract = "Cyclophosphamide therapy in doses greater than 50 mg/kg body weight has resulted in frank impairment of water excretion in 17 of 19 normally hydrated patients with cancer. Clinically, these patients developed hyponatremia, weight gain, and inappropriately concentrated urine during cyclophosphamide infusion, but without cyclophosphamide they excreted water loads normally. The decrease in serum osmolarity (range, 5 to 41 milliosmols/litre) and rise in urine osmolarity (range, 309 to 798 milliosmols/litre) occurred 4 to 12 hours after cyclophosphamide infusion, lasted up to 20 hours, and was related temporally with the urinary excretion of active alkylating metabolite(s) of the drug. Treatment of four cancer patients with cytosine arabinoside failed to provoke water intoxication. The mechanism of cyclophosphamide induced impairment of water excretion is unclear. Tumor release of antidiuretic hormone after cyclophosphamide administration seems unlikely since the study group included patients with leukemia and aplastic anemia without tumor. The likelihood and self limited time course of impaired water excretion during high dose cyclophosphamide treatment should be recognized because such patients are invariably waterloaded to prevent uric acid lithiasis and drug related cystitis.",
author = "Defronzo, {Ralph A} and H. Braine and Colvin, {O. M.} and Davis, {P. J.}",
year = "1973",
language = "English (US)",
volume = "78",
pages = "861--869",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "6",

}

TY - JOUR

T1 - Water intoxication in man after cyclophosphamide therapy

T2 - Time course and relation to drug activation

AU - Defronzo, Ralph A

AU - Braine, H.

AU - Colvin, O. M.

AU - Davis, P. J.

PY - 1973

Y1 - 1973

N2 - Cyclophosphamide therapy in doses greater than 50 mg/kg body weight has resulted in frank impairment of water excretion in 17 of 19 normally hydrated patients with cancer. Clinically, these patients developed hyponatremia, weight gain, and inappropriately concentrated urine during cyclophosphamide infusion, but without cyclophosphamide they excreted water loads normally. The decrease in serum osmolarity (range, 5 to 41 milliosmols/litre) and rise in urine osmolarity (range, 309 to 798 milliosmols/litre) occurred 4 to 12 hours after cyclophosphamide infusion, lasted up to 20 hours, and was related temporally with the urinary excretion of active alkylating metabolite(s) of the drug. Treatment of four cancer patients with cytosine arabinoside failed to provoke water intoxication. The mechanism of cyclophosphamide induced impairment of water excretion is unclear. Tumor release of antidiuretic hormone after cyclophosphamide administration seems unlikely since the study group included patients with leukemia and aplastic anemia without tumor. The likelihood and self limited time course of impaired water excretion during high dose cyclophosphamide treatment should be recognized because such patients are invariably waterloaded to prevent uric acid lithiasis and drug related cystitis.

AB - Cyclophosphamide therapy in doses greater than 50 mg/kg body weight has resulted in frank impairment of water excretion in 17 of 19 normally hydrated patients with cancer. Clinically, these patients developed hyponatremia, weight gain, and inappropriately concentrated urine during cyclophosphamide infusion, but without cyclophosphamide they excreted water loads normally. The decrease in serum osmolarity (range, 5 to 41 milliosmols/litre) and rise in urine osmolarity (range, 309 to 798 milliosmols/litre) occurred 4 to 12 hours after cyclophosphamide infusion, lasted up to 20 hours, and was related temporally with the urinary excretion of active alkylating metabolite(s) of the drug. Treatment of four cancer patients with cytosine arabinoside failed to provoke water intoxication. The mechanism of cyclophosphamide induced impairment of water excretion is unclear. Tumor release of antidiuretic hormone after cyclophosphamide administration seems unlikely since the study group included patients with leukemia and aplastic anemia without tumor. The likelihood and self limited time course of impaired water excretion during high dose cyclophosphamide treatment should be recognized because such patients are invariably waterloaded to prevent uric acid lithiasis and drug related cystitis.

UR - http://www.scopus.com/inward/record.url?scp=0015849244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015849244&partnerID=8YFLogxK

M3 - Article

VL - 78

SP - 861

EP - 869

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 6

ER -